

FILE COPY

PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/880,748
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	June 15, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1631
				Examiner Name	C. Ly
				Attorney Docket Number	PF523P1
Sheet	1	of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PA-D	A	6,297,367-B1	10-02-2001	Chiron Corporation	
	B	6,562,579-B1	05-13-2003	Human Genome Sciences, Inc.	
	C	6,403,770-B1	06-11-2002	Human Genome Sciences	
	D	US20010010925-A1	08-02-2001	Wiley, S.R.	
	E	US20020055624-A1	05-09-2002	Wiley, S.R.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
PA-D	F	WO97/33902-A1	09-18-1997	Human Genome Sciences		
PA-D	G	WO98/18921-A1	05-07-1998	Human Genome Sciences		
PA-D	H	WO98/27114-A2	06-25-1998	Schering		
PA-D	I	EP-0869180-A1	10-07-1998	SmithKline Beecham		
PA-D	J	WO98/55620-A1	12-10-1998	Regeneron		
PA-D	K	WO98/55621-A1	12-10-1998	Regeneron		
PA-D	L	WO99/11791-A2	03-11-1999	University of Washington		
PA-D	M	WO99/12964-A2	03-18-1999	Biogen		
PA-D	N	WO99/33980-A2	07-08-1999	Chiron		
PA-D	O	EP-0921194-A2	06-09-1999	Eli Lilly		
PA-D	P	WO00/26244-A2	05-11-2000	U.S. Government - DHHS		
PA-D	Q	WO00/39295-A1	07-06-2000	Glaxo Group Limited		
PA-D	R	WO00/40716-A2	07-13-2000	Zymogenetics		
PA-D	S	WO00/43032-A2	07-27-2000	Biogen		
PA-D	T	WO00/47740-A2	08-17-2000	Amgen, Inc.		
PA-D	U	WO00/45836-A1	08-10-2000	Res. Dev. Foundation		
PA-D	V	WO00/50597-A2	08-31-2000	Human Genome Sciences		
PA-D	W	WO00/60079-A2	10-12-2000	Chiron Corporation		
PA-D	X	WO00/67034-A1	11-09-2000	Immunex Corporation		
PA-D	Y	WO00/68378-A1	11-16-2000	National Jewish Medical and Research Center		
PA-D	Z	WO00/77256-A1	12-21-2000	Human Genome Sciences		
PA-D	AA	WO01/40466-A2	06-07-2001	Genentech		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Patricia A. Duffy	Date Considered	1/04
--------------------	-------------------	-----------------	------



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/880,748
				Filing Date	June 15, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1631
				Examiner Name	C. Ly
				Attorney Docket Number	PF523P1
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PAD.	AB	ASHKENAZI, ET AL., Response, Nature Immunology, (2000) 1:179.	
PAD.	AC	BAUMGARTH, Nicole, Secreted IgM versus BlyS in Germinal Center Formation, Nature Immunology, (2000) 1:179.	
PAD.	AD	BATTEN ET AL., BAFF Mediates Survival of Peripheral Immature B Lymphocytes. The Journal of Experimental Medicine, (2000) 192:1453-65.	
PAD.	AE	CHEEMA et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases, Arthritis and Rheumatism (2001) 44:1313-1319.	
PAD.	AF	CYSTER, JASON G., B Cells on the Front Line, Nature Immunology, (2000) 1:9-10.	
PAD.	AG	DO ET AL., Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response, The Journal of Experimental Medicine, (2000) 192:953-964.	
PAD.	AH	DORNER and PUTTERMAN, B cells, BAFF/zTNF4, TACI, and Systemic Lupus Erythematosus, Arthritis Research (2001) 3:197-9.	
PAD.	AI	GROSS ET AL., TACI and BCMA are receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease, Nature, (2000) 404:995-999.	
PAD.	AJ	HATZOGLOU ET AL., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, TRAF3 and Activates NF-kB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, The Journal of Immunology, (2000) 165:1322-1330.	
PAD.	AK	HU ET AL., Characterization of TNFRSF19, a Novel Member of the Tumor Necrosis Factor Receptor Superfamily, Genomics, 62:1023-107 (1999).	
PAD.	AL	KHARE ET AL., Severe B Cell Hyperplasia and autoimmune disease in TALL-1 transgenic mice, The Proceedings of the National Academy of Sciences, (2000) 97:3370-3375.	
PAD.	AM	LAABI ET AL., Lymphocyte Survival-Ignorance is BlyS, Science, (2001) 289:883.	
PAD.	AN	MACKAY ET AL., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations, The Journal of Experimental Medicine, (1999) 190:1697-1710.	
PAD.	AO	MARSTERS, ET AL., Interaction of the TNF Homologues BlyS and APRIL with the TNF Receptor Homologues BCMA and TACI, Current Biology, (2000) 10:785-788.	
PAD.	AP	MOORE ET AL., BlyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, Science, (1999) 285:260-263.	
PAD.	AQ	MUKHOPADHAY ET AL., Identification and Characterization of a Novel Cytokine, THANK, A TNF Homologue That Activates Apoptosis, Nuclear Factor-KB, and c-Jun NH2 Terminal Kinase (1999) The Journal of Biological Chemistry 274:15978-81.	
PAD.	AR	NARDELLI ET AL., Synthesis and Release of B-lymphocyte Stimulator from Myeloid Cells, Blood, (2001) 97:198-204.	
PAD.	AS	PARRY ET AL., Pharmacokinetics and Immunological Effects of Exogenously Administered Recombinant Human B Lymphocyte Stimulator (BlyS) in Mice, The Journal of Pharmacology and Experimental Therapeutics, (2001) 296:396-404.	
PAD.	AT	SCHNEIDER ET AL., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, The Journal of Experimental Medicine, (1999) 189:1747-1756.	
PAD.	AU	SHU ET AL., TALL-1 is a Novel Member of the TNF Family that is Down-Regulated by Mitogens, Journal of Leukocyte Biology, (1999) 65:680-683.	
PAD.	AV	THOMPSON ET AL., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population, The Journal of Experimental Medicine, (2000) 192:129-135.	
PAD.	AW	TRIBOULEY ET AL, Characterization of a New Member of the TNF Family Expressed on Antigen Presenting Cells, (1999) Biological Chemistry 380:1443-7.	

Examiner Signature	PATRICIA A. DUFFY	Date Considered	7/04
--------------------	-------------------	-----------------	------



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/880,748
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	June 15, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1631
				Examiner Name	C. Ly
				Attorney Docket Number	PF523P1
Sheet	3	of	3		

PAY	AX	WARE, CARL, APRIL and BAFF Connect Autoimmunity and Cancer. The Journal of Experimental Medicine (2000) 192:F35-F37.	
PAY	AY	XIA ET AL., TAC1 Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, The Journal of Experimental Medicine, (2000) 192:137-143.	
PAY	AZ	YAN ET AL., Identification of a receptor for BLyS Demonstrates a Crucial Role in Humoral Immunity, Nature Immunology, (2000) 1:37-41.	
PAY	BA	YU ET AL., APRIL and TALL-1 and Receptors BCMA and TAC1: System for Regulating Humoral Immunity, Nature Immunology, (2000) 1:252-256.	
PAY	BB	ZHANG ET AL., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, The Journal of Immunology, (2001) 166:6-10.	
PAY	BC	KANAKARAJ ET AL., BLyS Binds to B Cells With High Affinity and Induces Activation of the Transcription Factors NF-kB and Elf-1, Cytokine (2001) 13:25-31.	
PAY	BD	WU ET AL., Tumor Necrosis Factor (TNF) Receptor Superfamily Member TAC1 Is a High Affinity Receptor for TNF Family Members APRIL and BLyS, The Journal of Biological Chemistry (2000) 275:35478-35485.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	PATRICIA A. DUFFY	Date Considered	1/04
--------------------	-------------------	-----------------	------



File copy

PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/880,748
				Filing Date	June 15, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1631
				Examiner Name	C. Ly
Sheet	1	of	1	Attorney Docket Number	PF523P1

RECEIVED

DEC 05 2003

TECH CENTER 1600/2901

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
DAD	BE	US20030012783-A1	01-16-2003	KINDSVOGEL, W.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
PAD	BF	WO01/87977-A2	11-22-2001	AMGEN INC.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.